CMP-001

About CAMP4 Therapeutics

CAMP4 Therapeutics is a clinical-stage biotech company developing first-in-class antisense oligonucleotide (ASO) therapeutics that upregulate gene expression by targeting regulatory RNA. The company has established a proprietary RAP Platform® to map gene-regulatory circuits and has advanced its lead program, CMP-001 for urea cycle disorders, into Phase 1/2 clinical development. CAMP4's strategy leverages its platform to build a pipeline in CNS and metabolic diseases while seeking strategic partnerships to expand its reach. The company is publicly traded and led by a team with deep expertise in RNA biology, drug development, and corporate strategy.

Therapeutic Areas